QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program

  • QIAGEN delivers on Q1 2019 outlook

    • Net sales of $348.7 million (+1.5% actual, +6.1% at constant
      exchange rates, or CER vs. ~5-6% CER outlook)
    • Diluted EPS of $0.13; adj. EPS of $0.27 ($0.28 CER vs.
      ~$0.26-0.27 CER outlook)
  • Sample to Insight portfolio fueled by dynamic innovation and
    disruptive solutions

    • FDA approval of new therascreen companion diagnostic for
      FGFR biomarker
    • QuantiFERON-TB grows 15% CER, benefits of new automation options
    • European rollout progressing for QIAstat-Dx and NeuMoDx
      automation systems
    • Strong QIAsymphony placements in line with 2019 goal and
      consumables growth
    • New cancer research products in liquid biopsy, NGS panels with
  • New $100 million share repurchase program planned
  • QIAGEN reaffirms 2019 outlook for growth in net sales and adjusted
    EPS (at CER)

VENLO, Netherlands–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24QGEN&src=ctag” target=”_blank”gt;$QGENlt;/agt;–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced
results of operations for the first quarter of 2019, meeting its outlook
for net sales growth at constant exchange rates, or CER, and exceeding
the outlook for adjusted earnings per share at CER while driving global
expansion of its Sample to Insight portfolio of molecular testing

“Our performance for the first quarter of 2019 was in line with our
outlook for solid sales growth and continued improvements in
profitability. QIAGEN is reaffirming the full-year outlook set for this
year,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “We have
made significant progress in 2019 on advancing our portfolio of
differentiated Sample to Insight solutions and are looking forward to
delivering on its value.”

“We are well positioned to achieve our goals for full-year sales growth,
and to deliver faster growth particularly in the second half of 2019
given the success of our growth initiatives as well as the soon
anticipated U.S. approval of the QIAstat-Dx system for multiplex
syndromic testing. Our QuantiFERON latent TB test grew in line with the
2019 sales target range in the first quarter of 2019, and we announced
additional automation options for this important contributor in the
global fight against tuberculosis. We also expanded our portfolio of
solutions for next-generation sequencing, which remains on track to
achieve $190 million of sales in 2019 compared to $140 million in 2018,
with the launch of new liquid biopsy and gene panels integrated with
QIAGEN bioinformatics solutions. The launch of two new fully integrated
molecular testing solutions – QIAstat-Dx and NeuMoDx for integrated
molecular laboratory testing – are progressing well in Europe, are
receiving a very positive acceptance and we are ready to capture share
gains and growth opportunities in their very large target markets. Our
teams are developing a broad range of tests to further expand the
utility of these novel systems. In Precision Medicine, we are pleased by
the breakthrough U.S. regulatory approval for a new therascreen companion
diagnostic that tests for variants of the biomarker FGFR to help guide
treatment decisions for patients with urothelial cancer. We are moving
ahead with the transformation of QIAGEN and are continuing to execute on
a strategy to maximize the value of this differentiated portfolio of
molecular testing solutions along the continuum from Life Sciences
research to Molecular Diagnostics.”

the full press release incl. financial tables here (PDF)


John Gilardi
Vice President Corporate Communications and Investor
+49 2103 29 11711 and +1 240 686 2222

Phoebe Loh
Associate Director Investor Relations
+49 2103 29

Dr. Thomas Theuringer
Senior Director Public Relations and Digital
+49 2103 29 11826 and +1 240 686 7425

Thank you for donating to DutchNews.nl.

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation